XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
OVERLAYS
Fund
Benchmark
3Y · NAV total return · GBP
Polar Capital Funds PLC - Biotechnology Fund - I EUR Inc: holdings, performance and fees
1Y return+52.3%
3Y return+101.0%
5Y return+87.9%
OCF (ongoing charge)1.07%
Top 10 holdings
| Holding | Weight |
|---|---|
| AMGEN INC. | 4.6% |
| XENON PHARMACEUTICALS INC. | 4.3% |
| ARCUTIS BIOTHERAPEUTICS INC | 4.3% |
| RHYTHM PHARMACEUTICALS, INC. | 4.0% |
| ARGENX SE | 3.8% |
| ASCENDIS PHARMA A/S | 3.8% |
| ENLIVEN THERAPEUTICS INC | 3.6% |
| COGENT BIOSCIENCES INC | 3.3% |
| MADRIGAL PHARMACEUTICALS INC | 3.2% |
| CYTOKINETICS, INCORPORATED | 3.1% |
Top sectors
- Health Care88.4%
- Money Market11.6%
Top countries
- USA69.9%
- Cash & Cash Equivalents11.6%
- Netherlands5.0%
- Canada4.3%
- Denmark3.8%
Holdings, sector and country weightings and performance as reported by FE fundinfo. Weightings are a percentage of the portfolio and may not sum to 100.
AI FORECAST · 12-MONTH
Powered by Claude
FREE PREVIEW
Sign up free to unlock the full AI analysis →
UP—
PREMIUM
PREMIUM
Positives
Risks
600 adviser votes
Upgrade for full forecast →
This is an illustrative, model-generated scenario based on stated assumptions. It is not a prediction, a forecast of actual returns, or investment advice. Outcomes may differ materially. Past performance is not a guide to future returns. Capital is at risk.
PORTFOLIO BREAKDOWN